Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (11345)	11/5/2002 11:00:36 AM
From: twentyfirstcenturyfox	Read Replies (2) \| Respond to of 14101

<It works so much better than the other products it is had to believe we are still waiting.> Thanks, very decent of you users to all share your Pennsaids user experiences. I wish I could get it, as my wife(shewhoisgoingtokillmesoonifwestaybelow3dollars) and I suffer from occasional painful ailments that it would surely help. We who need it do have a different perspective. We will keep hoping, as to the general availability of this product. As investors, we continue to be disappointed by management's deficiencies. They appear to be great at developing drug delivery technologies. They appear to be lousy at managing a business. A good reflection of the state of the latter: One of my non SI DMX friends (a sophisticated investor) writes: <I received the 2002 annual report for DMX in the mail yesterday. It is a well produced document and the front section reads well and is informative regarding the scientific aspects of DMX activities. However, information on the management of the business operations and finances is very sparse and I did not learn anything new about the company from the report. I would have liked to know more about what the company spent $13 million on, the reasons why sales were down over 50% and an explanation about poor Pennsaid sales in the UK and dismissal of Provalis as UK agent. According to the report, selling expenses increased from $1.4 million to $3.3 million during the year "reflecting the cost of recruiting and training medical representatives in anticipation of Pennsaid regulatory approval in Canada." Believe it or not, 36 persons were taken on for this task in the absence of Pennsaid approval. I wonder why this decision was taken to recruit these people and on what basis did DMX assume that they were going to get approval? Although the report is silent on this matter, it would appear that this is a continuing cost to the company ($2 million annually) as there is no mention of having disbanded the sales force. It seems to me that this company has some talent with pharma science but that operational management skills and savvy are deficient.> I, too, do despair at the lack of business acumen in this company and, to be brutally frank, on this board. The majority of posters appear to follow this viewpoint: <If we get FDA approval, we ought to get a 50 million USA marketing deal, hell, 150-250million. If we don't get approval we are dead.> Great business plan. (Jim, before you jump on me, in your usual style, I mean to be sarcastic about the company, and not about you). Meanwhile, a remark by the PRESIDENT of this company at its no-mike agm Q&A session attracts no criticism, namely (I paraphrase): <Q: why did you sell your shares and why do you have no shares in the company at this time? Mrs Keeler: a person is entitled to a private life.> If I had been there, my response to that would have been a polite version of <F.ck right off, lady!>. I hold a lot of shares. I hope this company does get FDA approval: - both for the humanitarian aspect, (as it will then have the resources to develope and bring WF-10 to market); - and so that I can get some return back on my investment. It is worth saying; again and again: the attitude of management at this company towards it independent investors sucks to the point of being criminal. all imho. Fox.